Efficient cell expansion in vitro is essential to commercialization of human MSC as a cellular therapy. The cost of goods sold (COGS) is dramatically affected by how long it takes to expand the cells in vitro and the cell yield determines the number of doses generated for profit. Therefore, maximizing MSC growth in culture is critical for the success of MSC-based cellular therapies. Studies by others have shown that temperature differences in cell production can adversely affect cell yields. Here we study the effects of variability in temperature and CO2, like changes seen during routine cell handling in a room air BSC, on human MSC yield. We cultured human bone marrow mesenchymal stromal/stem cells for 8 biweekly subpassages (P4-P12) with ...
Background: Cell-based therapies have the potential to become treatment options for many diseases, b...
Industry trends in regenerative medicine highlight a critical need for closed, single use cell cultu...
Background: The cost effective production of hMSCs for off-the-shelf and patient specific therapies ...
Standardization is crucial when culturing cells including human embryonic stem cells (hESCs) which a...
Human bone marrow multipotent mesenchymal stromal cells (hBM-MSC) represent an appealing source of a...
Industry trends in regenerative medicine show an increased need for scalable and closed manufacturin...
Progress in regenerative medicines over the past ten years have led to an important research mobilis...
The manufacture of complex therapeutic proteins using mammalian cells is well established, with seve...
Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell therapy but their expansio...
Mesenchymal stem cell (MSC) based therapies are promising for a large spectrum of unmet medical need...
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell ba...
Background: Culture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when m...
Cultivation temperature is a key environmental parameter that influences cell growth and recombinant...
Production of human mesenchymal stem cells for allogeneic cell therapies requires scalable, cost-eff...
Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell therapy but their expansio...
Background: Cell-based therapies have the potential to become treatment options for many diseases, b...
Industry trends in regenerative medicine highlight a critical need for closed, single use cell cultu...
Background: The cost effective production of hMSCs for off-the-shelf and patient specific therapies ...
Standardization is crucial when culturing cells including human embryonic stem cells (hESCs) which a...
Human bone marrow multipotent mesenchymal stromal cells (hBM-MSC) represent an appealing source of a...
Industry trends in regenerative medicine show an increased need for scalable and closed manufacturin...
Progress in regenerative medicines over the past ten years have led to an important research mobilis...
The manufacture of complex therapeutic proteins using mammalian cells is well established, with seve...
Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell therapy but their expansio...
Mesenchymal stem cell (MSC) based therapies are promising for a large spectrum of unmet medical need...
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell ba...
Background: Culture-derived mesenchymal stromal cells (MSCs) exhibit variable characteristics when m...
Cultivation temperature is a key environmental parameter that influences cell growth and recombinant...
Production of human mesenchymal stem cells for allogeneic cell therapies requires scalable, cost-eff...
Human mesenchymal stromal cells (hMSCs) are excellent candidates for cell therapy but their expansio...
Background: Cell-based therapies have the potential to become treatment options for many diseases, b...
Industry trends in regenerative medicine highlight a critical need for closed, single use cell cultu...
Background: The cost effective production of hMSCs for off-the-shelf and patient specific therapies ...